nodes	percent_of_prediction	percent_of_DWPC	metapath
Mianserin—CYP1A2—Carmustine—melanoma	0.101	0.229	CbGbCtD
Mianserin—CYP1A2—Vemurafenib—melanoma	0.0798	0.181	CbGbCtD
Mianserin—CYP3A4—Temozolomide—melanoma	0.0763	0.173	CbGbCtD
Mianserin—CYP2D6—Vemurafenib—melanoma	0.0658	0.149	CbGbCtD
Mianserin—CYP1A2—Dacarbazine—melanoma	0.0612	0.139	CbGbCtD
Mianserin—CYP3A4—Vemurafenib—melanoma	0.0418	0.095	CbGbCtD
Mianserin—HTR1D—meninx—melanoma	0.0236	0.325	CbGeAlD
Mianserin—CYP3A4—Docetaxel—melanoma	0.0144	0.0326	CbGbCtD
Mianserin—Electrocardiogram QT prolonged—Vemurafenib—melanoma	0.00662	0.0399	CcSEcCtD
Mianserin—Arthritis—Vemurafenib—melanoma	0.00318	0.0191	CcSEcCtD
Mianserin—HTR2A—hindlimb—melanoma	0.00278	0.0383	CbGeAlD
Mianserin—HTR1D—blood vessel—melanoma	0.00267	0.0368	CbGeAlD
Mianserin—HTR2A—appendage—melanoma	0.00239	0.0329	CbGeAlD
Mianserin—HTR7—endothelium—melanoma	0.00231	0.0318	CbGeAlD
Mianserin—Hepatic enzyme increased—Temozolomide—melanoma	0.0023	0.0138	CcSEcCtD
Mianserin—HTR7—blood vessel—melanoma	0.00213	0.0293	CbGeAlD
Mianserin—Connective tissue disorder—Vemurafenib—melanoma	0.0021	0.0126	CcSEcCtD
Mianserin—HTR1F—head—melanoma	0.00204	0.028	CbGeAlD
Mianserin—Gynaecomastia—Carmustine—melanoma	0.00201	0.0121	CcSEcCtD
Mianserin—Eye disorder—Vemurafenib—melanoma	0.002	0.012	CcSEcCtD
Mianserin—Cardiac disorder—Vemurafenib—melanoma	0.00198	0.0119	CcSEcCtD
Mianserin—HRH2—skin of body—melanoma	0.00194	0.0267	CbGeAlD
Mianserin—Angiopathy—Vemurafenib—melanoma	0.00194	0.0117	CcSEcCtD
Mianserin—Mediastinal disorder—Vemurafenib—melanoma	0.00192	0.0116	CcSEcCtD
Mianserin—Arthritis—Bleomycin—melanoma	0.00192	0.0116	CcSEcCtD
Mianserin—Lethargy—Dactinomycin—melanoma	0.00178	0.0107	CcSEcCtD
Mianserin—Nasal congestion—Temozolomide—melanoma	0.00173	0.0104	CcSEcCtD
Mianserin—Diplopia—Carmustine—melanoma	0.00163	0.00983	CcSEcCtD
Mianserin—Arthralgia—Vemurafenib—melanoma	0.00158	0.00953	CcSEcCtD
Mianserin—Myalgia—Vemurafenib—melanoma	0.00158	0.00953	CcSEcCtD
Mianserin—Diplopia—Temozolomide—melanoma	0.00158	0.0095	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00157	0.00946	CcSEcCtD
Mianserin—Pancytopenia—Bleomycin—melanoma	0.00154	0.00924	CcSEcCtD
Mianserin—HTR7—neck—melanoma	0.00152	0.021	CbGeAlD
Mianserin—Nervous system disorder—Vemurafenib—melanoma	0.00149	0.00896	CcSEcCtD
Mianserin—Skin disorder—Vemurafenib—melanoma	0.00147	0.00887	CcSEcCtD
Mianserin—HTR2A—endothelium—melanoma	0.00144	0.0198	CbGeAlD
Mianserin—DRD3—head—melanoma	0.00144	0.0198	CbGeAlD
Mianserin—Pancytopenia—Dactinomycin—melanoma	0.00143	0.00862	CcSEcCtD
Mianserin—Breast disorder—Temozolomide—melanoma	0.00143	0.00858	CcSEcCtD
Mianserin—HTR1D—eye—melanoma	0.00142	0.0196	CbGeAlD
Mianserin—Hypotension—Vemurafenib—melanoma	0.00142	0.00853	CcSEcCtD
Mianserin—Neutropenia—Dactinomycin—melanoma	0.00141	0.00849	CcSEcCtD
Mianserin—HTR6—head—melanoma	0.00138	0.0191	CbGeAlD
Mianserin—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00138	0.00832	CcSEcCtD
Mianserin—Pancytopenia—Carmustine—melanoma	0.00134	0.00807	CcSEcCtD
Mianserin—HTR2A—blood vessel—melanoma	0.00133	0.0183	CbGeAlD
Mianserin—Neutropenia—Carmustine—melanoma	0.00132	0.00794	CcSEcCtD
Mianserin—Gastrointestinal disorder—Vemurafenib—melanoma	0.00131	0.00789	CcSEcCtD
Mianserin—Fatigue—Vemurafenib—melanoma	0.00131	0.00787	CcSEcCtD
Mianserin—Constipation—Vemurafenib—melanoma	0.0013	0.00781	CcSEcCtD
Mianserin—Pancytopenia—Temozolomide—melanoma	0.00129	0.0078	CcSEcCtD
Mianserin—OPRK1—head—melanoma	0.00128	0.0176	CbGeAlD
Mianserin—Neutropenia—Temozolomide—melanoma	0.00128	0.00768	CcSEcCtD
Mianserin—HRH2—head—melanoma	0.00127	0.0174	CbGeAlD
Mianserin—Erectile dysfunction—Temozolomide—melanoma	0.00126	0.00756	CcSEcCtD
Mianserin—Agranulocytosis—Dactinomycin—melanoma	0.00125	0.00755	CcSEcCtD
Mianserin—Weight increased—Temozolomide—melanoma	0.00124	0.00747	CcSEcCtD
Mianserin—Hepatitis—Dactinomycin—melanoma	0.00121	0.00726	CcSEcCtD
Mianserin—HTR2B—skin of body—melanoma	0.00115	0.0159	CbGeAlD
Mianserin—Hepatobiliary disease—Temozolomide—melanoma	0.00115	0.00692	CcSEcCtD
Mianserin—Connective tissue disorder—Carmustine—melanoma	0.00111	0.00668	CcSEcCtD
Mianserin—Hepatitis—Temozolomide—melanoma	0.00109	0.00657	CcSEcCtD
Mianserin—Asthenia—Vemurafenib—melanoma	0.00109	0.00655	CcSEcCtD
Mianserin—Cardiac failure—Docetaxel—melanoma	0.00108	0.00647	CcSEcCtD
Mianserin—Pruritus—Vemurafenib—melanoma	0.00107	0.00646	CcSEcCtD
Mianserin—Connective tissue disorder—Temozolomide—melanoma	0.00107	0.00646	CcSEcCtD
Mianserin—DRD2—eye—melanoma	0.00107	0.0148	CbGeAlD
Mianserin—Lethargy—Docetaxel—melanoma	0.00107	0.00645	CcSEcCtD
Mianserin—DRD2—retina—melanoma	0.00106	0.0146	CbGeAlD
Mianserin—Eye disorder—Carmustine—melanoma	0.00106	0.00635	CcSEcCtD
Mianserin—Anaemia—Bleomycin—melanoma	0.00104	0.00627	CcSEcCtD
Mianserin—Eye disorder—Temozolomide—melanoma	0.00102	0.00614	CcSEcCtD
Mianserin—Tinnitus—Temozolomide—melanoma	0.00102	0.00613	CcSEcCtD
Mianserin—Cardiac disorder—Temozolomide—melanoma	0.00101	0.0061	CcSEcCtD
Mianserin—Leukopenia—Bleomycin—melanoma	0.00101	0.00607	CcSEcCtD
Mianserin—Dizziness—Vemurafenib—melanoma	0.001	0.00604	CcSEcCtD
Mianserin—Angiopathy—Temozolomide—melanoma	0.00099	0.00596	CcSEcCtD
Mianserin—Mental disorder—Carmustine—melanoma	0.000989	0.00596	CcSEcCtD
Mianserin—Mediastinal disorder—Temozolomide—melanoma	0.000984	0.00592	CcSEcCtD
Mianserin—Anaemia—Dactinomycin—melanoma	0.000971	0.00584	CcSEcCtD
Mianserin—Myalgia—Bleomycin—melanoma	0.000959	0.00577	CcSEcCtD
Mianserin—Rash—Vemurafenib—melanoma	0.000957	0.00576	CcSEcCtD
Mianserin—Mental disorder—Temozolomide—melanoma	0.000956	0.00576	CcSEcCtD
Mianserin—Dermatitis—Vemurafenib—melanoma	0.000956	0.00575	CcSEcCtD
Mianserin—Headache—Vemurafenib—melanoma	0.00095	0.00572	CcSEcCtD
Mianserin—HTR2A—neck—melanoma	0.00095	0.0131	CbGeAlD
Mianserin—Breast disorder—Docetaxel—melanoma	0.000948	0.00571	CcSEcCtD
Mianserin—Leukopenia—Dactinomycin—melanoma	0.00094	0.00566	CcSEcCtD
Mianserin—Confusional state—Bleomycin—melanoma	0.000927	0.00558	CcSEcCtD
Mianserin—Tremor—Carmustine—melanoma	0.000921	0.00555	CcSEcCtD
Mianserin—Oedema—Bleomycin—melanoma	0.000919	0.00553	CcSEcCtD
Mianserin—Anaemia—Carmustine—melanoma	0.000909	0.00547	CcSEcCtD
Mianserin—Agitation—Carmustine—melanoma	0.000903	0.00544	CcSEcCtD
Mianserin—Thrombocytopenia—Bleomycin—melanoma	0.0009	0.00542	CcSEcCtD
Mianserin—Myalgia—Dactinomycin—melanoma	0.000894	0.00538	CcSEcCtD
Mianserin—Tremor—Temozolomide—melanoma	0.00089	0.00536	CcSEcCtD
Mianserin—HRH2—lymph node—melanoma	0.000886	0.0122	CbGeAlD
Mianserin—Leukopenia—Carmustine—melanoma	0.00088	0.0053	CcSEcCtD
Mianserin—Anaemia—Temozolomide—melanoma	0.000878	0.00529	CcSEcCtD
Mianserin—Agitation—Temozolomide—melanoma	0.000873	0.00526	CcSEcCtD
Mianserin—Pancytopenia—Docetaxel—melanoma	0.000861	0.00518	CcSEcCtD
Mianserin—Hypotension—Bleomycin—melanoma	0.000859	0.00517	CcSEcCtD
Mianserin—Oedema—Dactinomycin—melanoma	0.000857	0.00516	CcSEcCtD
Mianserin—Vertigo—Temozolomide—melanoma	0.000854	0.00514	CcSEcCtD
Mianserin—Convulsion—Carmustine—melanoma	0.000852	0.00513	CcSEcCtD
Mianserin—Leukopenia—Temozolomide—melanoma	0.00085	0.00512	CcSEcCtD
Mianserin—Hypertension—Carmustine—melanoma	0.000849	0.00511	CcSEcCtD
Mianserin—Neutropenia—Docetaxel—melanoma	0.000848	0.0051	CcSEcCtD
Mianserin—HRH1—eye—melanoma	0.000846	0.0117	CbGeAlD
Mianserin—Thrombocytopenia—Dactinomycin—melanoma	0.000839	0.00505	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Bleomycin—melanoma	0.000837	0.00504	CcSEcCtD
Mianserin—Myalgia—Carmustine—melanoma	0.000837	0.00504	CcSEcCtD
Mianserin—SLC6A3—head—melanoma	0.000827	0.0114	CbGeAlD
Mianserin—ADRA2C—mammalian vulva—melanoma	0.000827	0.0114	CbGeAlD
Mianserin—Paraesthesia—Bleomycin—melanoma	0.000825	0.00497	CcSEcCtD
Mianserin—Weight increased—Docetaxel—melanoma	0.000825	0.00497	CcSEcCtD
Mianserin—Convulsion—Temozolomide—melanoma	0.000823	0.00496	CcSEcCtD
Mianserin—Hypertension—Temozolomide—melanoma	0.00082	0.00494	CcSEcCtD
Mianserin—Confusional state—Carmustine—melanoma	0.000809	0.00487	CcSEcCtD
Mianserin—Myalgia—Temozolomide—melanoma	0.000809	0.00487	CcSEcCtD
Mianserin—Arthralgia—Temozolomide—melanoma	0.000809	0.00487	CcSEcCtD
Mianserin—HTR1D—head—melanoma	0.000808	0.0111	CbGeAlD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000803	0.00484	CcSEcCtD
Mianserin—Oedema—Carmustine—melanoma	0.000802	0.00483	CcSEcCtD
Mianserin—HTR2C—head—melanoma	0.0008	0.011	CbGeAlD
Mianserin—Dry mouth—Temozolomide—melanoma	0.000791	0.00476	CcSEcCtD
Mianserin—Jaundice—Docetaxel—melanoma	0.000788	0.00474	CcSEcCtD
Mianserin—Thrombocytopenia—Carmustine—melanoma	0.000786	0.00473	CcSEcCtD
Mianserin—Tachycardia—Carmustine—melanoma	0.000783	0.00471	CcSEcCtD
Mianserin—Confusional state—Temozolomide—melanoma	0.000782	0.00471	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000781	0.0047	CcSEcCtD
Mianserin—Oedema—Temozolomide—melanoma	0.000775	0.00467	CcSEcCtD
Mianserin—Hepatobiliary disease—Docetaxel—melanoma	0.000765	0.0046	CcSEcCtD
Mianserin—Nervous system disorder—Temozolomide—melanoma	0.00076	0.00458	CcSEcCtD
Mianserin—Thrombocytopenia—Temozolomide—melanoma	0.000759	0.00457	CcSEcCtD
Mianserin—SLC6A4—head—melanoma	0.000758	0.0104	CbGeAlD
Mianserin—Feeling abnormal—Bleomycin—melanoma	0.000757	0.00456	CcSEcCtD
Mianserin—Agranulocytosis—Docetaxel—melanoma	0.000755	0.00454	CcSEcCtD
Mianserin—CYP2B6—skin of body—melanoma	0.000754	0.0104	CbGeAlD
Mianserin—Skin disorder—Temozolomide—melanoma	0.000753	0.00453	CcSEcCtD
Mianserin—HTR2B—head—melanoma	0.000751	0.0103	CbGeAlD
Mianserin—Hypotension—Carmustine—melanoma	0.00075	0.00451	CcSEcCtD
Mianserin—Fatigue—Dactinomycin—melanoma	0.000739	0.00445	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Carmustine—melanoma	0.000731	0.0044	CcSEcCtD
Mianserin—Hepatitis—Docetaxel—melanoma	0.000726	0.00437	CcSEcCtD
Mianserin—Paraesthesia—Carmustine—melanoma	0.000721	0.00434	CcSEcCtD
Mianserin—Somnolence—Carmustine—melanoma	0.000713	0.00429	CcSEcCtD
Mianserin—Connective tissue disorder—Docetaxel—melanoma	0.000713	0.00429	CcSEcCtD
Mianserin—HTR2A—eye—melanoma	0.000707	0.00973	CbGeAlD
Mianserin—Feeling abnormal—Dactinomycin—melanoma	0.000706	0.00425	CcSEcCtD
Mianserin—Musculoskeletal discomfort—Temozolomide—melanoma	0.000706	0.00425	CcSEcCtD
Mianserin—HTR2A—retina—melanoma	0.0007	0.00965	CbGeAlD
Mianserin—Paraesthesia—Temozolomide—melanoma	0.000696	0.00419	CcSEcCtD
Mianserin—Gastrointestinal disorder—Carmustine—melanoma	0.000693	0.00417	CcSEcCtD
Mianserin—Somnolence—Temozolomide—melanoma	0.000689	0.00415	CcSEcCtD
Mianserin—Constipation—Carmustine—melanoma	0.000686	0.00413	CcSEcCtD
Mianserin—Eye disorder—Docetaxel—melanoma	0.000678	0.00408	CcSEcCtD
Mianserin—Cardiac disorder—Docetaxel—melanoma	0.000674	0.00406	CcSEcCtD
Mianserin—HTR1A—head—melanoma	0.000673	0.00927	CbGeAlD
Mianserin—HRH1—mammalian vulva—melanoma	0.000671	0.00925	CbGeAlD
Mianserin—Gastrointestinal disorder—Temozolomide—melanoma	0.000669	0.00403	CcSEcCtD
Mianserin—Fatigue—Temozolomide—melanoma	0.000669	0.00402	CcSEcCtD
Mianserin—SLC6A2—head—melanoma	0.000668	0.00919	CbGeAlD
Mianserin—Constipation—Temozolomide—melanoma	0.000663	0.00399	CcSEcCtD
Mianserin—Feeling abnormal—Carmustine—melanoma	0.000661	0.00398	CcSEcCtD
Mianserin—Asthenia—Bleomycin—melanoma	0.00066	0.00397	CcSEcCtD
Mianserin—ADRA2A—mammalian vulva—melanoma	0.00066	0.00908	CbGeAlD
Mianserin—Angiopathy—Docetaxel—melanoma	0.000659	0.00396	CcSEcCtD
Mianserin—Mediastinal disorder—Docetaxel—melanoma	0.000654	0.00394	CcSEcCtD
Mianserin—Pruritus—Bleomycin—melanoma	0.00065	0.00392	CcSEcCtD
Mianserin—HTR7—head—melanoma	0.000643	0.00886	CbGeAlD
Mianserin—Feeling abnormal—Temozolomide—melanoma	0.000639	0.00385	CcSEcCtD
Mianserin—Mental disorder—Docetaxel—melanoma	0.000636	0.00383	CcSEcCtD
Mianserin—Asthenia—Dactinomycin—melanoma	0.000615	0.0037	CcSEcCtD
Mianserin—DRD2—head—melanoma	0.000608	0.00838	CbGeAlD
Mianserin—ADRA2C—head—melanoma	0.000591	0.00814	CbGeAlD
Mianserin—Anaemia—Docetaxel—melanoma	0.000584	0.00352	CcSEcCtD
Mianserin—Rash—Bleomycin—melanoma	0.00058	0.00349	CcSEcCtD
Mianserin—Dermatitis—Bleomycin—melanoma	0.000579	0.00349	CcSEcCtD
Mianserin—Asthenia—Carmustine—melanoma	0.000576	0.00347	CcSEcCtD
Mianserin—Syncope—Docetaxel—melanoma	0.000567	0.00341	CcSEcCtD
Mianserin—Leukopenia—Docetaxel—melanoma	0.000566	0.0034	CcSEcCtD
Mianserin—Asthenia—Temozolomide—melanoma	0.000556	0.00335	CcSEcCtD
Mianserin—Loss of consciousness—Docetaxel—melanoma	0.000555	0.00334	CcSEcCtD
Mianserin—Pruritus—Temozolomide—melanoma	0.000549	0.0033	CcSEcCtD
Mianserin—Convulsion—Docetaxel—melanoma	0.000547	0.0033	CcSEcCtD
Mianserin—Hypertension—Docetaxel—melanoma	0.000545	0.00328	CcSEcCtD
Mianserin—Rash—Dactinomycin—melanoma	0.000541	0.00325	CcSEcCtD
Mianserin—Myalgia—Docetaxel—melanoma	0.000538	0.00324	CcSEcCtD
Mianserin—Arthralgia—Docetaxel—melanoma	0.000538	0.00324	CcSEcCtD
Mianserin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000534	0.00322	CcSEcCtD
Mianserin—Dizziness—Carmustine—melanoma	0.000531	0.00319	CcSEcCtD
Mianserin—Dry mouth—Docetaxel—melanoma	0.000526	0.00317	CcSEcCtD
Mianserin—HTR2B—lymph node—melanoma	0.000526	0.00725	CbGeAlD
Mianserin—Confusional state—Docetaxel—melanoma	0.00052	0.00313	CcSEcCtD
Mianserin—Oedema—Docetaxel—melanoma	0.000516	0.0031	CcSEcCtD
Mianserin—Dizziness—Temozolomide—melanoma	0.000513	0.00309	CcSEcCtD
Mianserin—Shock—Docetaxel—melanoma	0.000507	0.00305	CcSEcCtD
Mianserin—Rash—Carmustine—melanoma	0.000506	0.00305	CcSEcCtD
Mianserin—Nervous system disorder—Docetaxel—melanoma	0.000506	0.00304	CcSEcCtD
Mianserin—Dermatitis—Carmustine—melanoma	0.000505	0.00304	CcSEcCtD
Mianserin—Thrombocytopenia—Docetaxel—melanoma	0.000505	0.00304	CcSEcCtD
Mianserin—Tachycardia—Docetaxel—melanoma	0.000503	0.00303	CcSEcCtD
Mianserin—Headache—Carmustine—melanoma	0.000503	0.00303	CcSEcCtD
Mianserin—Skin disorder—Docetaxel—melanoma	0.000501	0.00302	CcSEcCtD
Mianserin—CYP2B6—head—melanoma	0.000492	0.00677	CbGeAlD
Mianserin—Rash—Temozolomide—melanoma	0.000489	0.00294	CcSEcCtD
Mianserin—Dermatitis—Temozolomide—melanoma	0.000488	0.00294	CcSEcCtD
Mianserin—Headache—Temozolomide—melanoma	0.000486	0.00292	CcSEcCtD
Mianserin—Hypotension—Docetaxel—melanoma	0.000482	0.0029	CcSEcCtD
Mianserin—HRH1—head—melanoma	0.00048	0.00662	CbGeAlD
Mianserin—ADRA2A—head—melanoma	0.000472	0.0065	CbGeAlD
Mianserin—Musculoskeletal discomfort—Docetaxel—melanoma	0.00047	0.00283	CcSEcCtD
Mianserin—SLC6A2—lymph node—melanoma	0.000467	0.00644	CbGeAlD
Mianserin—Paraesthesia—Docetaxel—melanoma	0.000463	0.00279	CcSEcCtD
Mianserin—Somnolence—Docetaxel—melanoma	0.000458	0.00276	CcSEcCtD
Mianserin—Gastrointestinal disorder—Docetaxel—melanoma	0.000445	0.00268	CcSEcCtD
Mianserin—Fatigue—Docetaxel—melanoma	0.000445	0.00268	CcSEcCtD
Mianserin—Constipation—Docetaxel—melanoma	0.000441	0.00265	CcSEcCtD
Mianserin—Feeling abnormal—Docetaxel—melanoma	0.000425	0.00256	CcSEcCtD
Mianserin—ADRA2C—lymph node—melanoma	0.000414	0.0057	CbGeAlD
Mianserin—HTR2A—head—melanoma	0.000401	0.00553	CbGeAlD
Mianserin—Asthenia—Docetaxel—melanoma	0.00037	0.00223	CcSEcCtD
Mianserin—CYP2D6—head—melanoma	0.000365	0.00503	CbGeAlD
Mianserin—Pruritus—Docetaxel—melanoma	0.000365	0.0022	CcSEcCtD
Mianserin—Dizziness—Docetaxel—melanoma	0.000341	0.00205	CcSEcCtD
Mianserin—HRH1—lymph node—melanoma	0.000336	0.00463	CbGeAlD
Mianserin—ADRA2A—lymph node—melanoma	0.00033	0.00455	CbGeAlD
Mianserin—Rash—Docetaxel—melanoma	0.000325	0.00196	CcSEcCtD
Mianserin—Dermatitis—Docetaxel—melanoma	0.000325	0.00196	CcSEcCtD
Mianserin—Headache—Docetaxel—melanoma	0.000323	0.00194	CcSEcCtD
Mianserin—HTR2C—Signaling Pathways—PTEN—melanoma	6.63e-06	2.06e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CTNNB1—melanoma	6.61e-06	2.06e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—ERCC2—melanoma	6.61e-06	2.06e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—NFKB1—melanoma	6.59e-06	2.05e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MAPK3—melanoma	6.53e-06	2.03e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CXCL8—melanoma	6.5e-06	2.03e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling by GPCR—AKT1—melanoma	6.5e-06	2.02e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MMP9—melanoma	6.48e-06	2.02e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling by GPCR—AKT1—melanoma	6.46e-06	2.01e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—HRAS—melanoma	6.46e-06	2.01e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—CDKN1A—melanoma	6.46e-06	2.01e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PTEN—melanoma	6.44e-06	2.01e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—PIK3CA—melanoma	6.44e-06	2.01e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—NFKB1—melanoma	6.41e-06	2e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CXCL8—melanoma	6.4e-06	1.99e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CXCL8—melanoma	6.38e-06	1.99e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—HRAS—melanoma	6.36e-06	1.98e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MYC—melanoma	6.35e-06	1.98e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CDKN1B—melanoma	6.35e-06	1.98e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—PIK3CA—melanoma	6.35e-06	1.98e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—HRAS—melanoma	6.34e-06	1.98e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—PIK3CA—melanoma	6.34e-06	1.98e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—KRAS—melanoma	6.31e-06	1.96e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—PIK3CA—melanoma	6.3e-06	1.96e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling by GPCR—AKT1—melanoma	6.29e-06	1.96e-05	CbGpPWpGaD
Mianserin—DRD2—GPCR downstream signaling—AKT1—melanoma	6.28e-06	1.96e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PTEN—melanoma	6.26e-06	1.95e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	6.25e-06	1.95e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CDKN1B—melanoma	6.25e-06	1.95e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CDKN1B—melanoma	6.23e-06	1.94e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—VEGFA—melanoma	6.23e-06	1.94e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—TP53—melanoma	6.23e-06	1.94e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MDM2—melanoma	6.23e-06	1.94e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CASP3—melanoma	6.22e-06	1.94e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL2—melanoma	6.21e-06	1.94e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—MAPK1—melanoma	6.21e-06	1.94e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—EGFR—melanoma	6.21e-06	1.94e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—IL6—melanoma	6.18e-06	1.93e-05	CbGpPWpGaD
Mianserin—HTR2A—GPCR downstream signaling—AKT1—melanoma	6.18e-06	1.93e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—STAT3—melanoma	6.17e-06	1.92e-05	CbGpPWpGaD
Mianserin—HRH1—GPCR downstream signaling—AKT1—melanoma	6.17e-06	1.92e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CG—melanoma	6.16e-06	1.92e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—NRAS—melanoma	6.15e-06	1.92e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—TP53—melanoma	6.14e-06	1.91e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—ERBB2—melanoma	6.14e-06	1.91e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—TP53—melanoma	6.13e-06	1.91e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CASP3—melanoma	6.12e-06	1.91e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL2—melanoma	6.11e-06	1.91e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CASP3—melanoma	6.11e-06	1.9e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL2—melanoma	6.1e-06	1.9e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—TP53—melanoma	6.09e-06	1.9e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—IL6—melanoma	6.08e-06	1.9e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—IL6—melanoma	6.07e-06	1.89e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CCND1—melanoma	6.06e-06	1.89e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CB—melanoma	6.06e-06	1.89e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—VEGFA—melanoma	6.02e-06	1.87e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CTNNB1—melanoma	6e-06	1.87e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—VEGFA—melanoma	5.98e-06	1.86e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CCND1—melanoma	5.96e-06	1.86e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—HRAS—melanoma	5.96e-06	1.86e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—STAT3—melanoma	5.96e-06	1.86e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CCND1—melanoma	5.95e-06	1.85e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PPARG—melanoma	5.95e-06	1.85e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—NRAS—melanoma	5.94e-06	1.85e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—STAT3—melanoma	5.93e-06	1.85e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—NRAS—melanoma	5.91e-06	1.84e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CTNNB1—melanoma	5.9e-06	1.84e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MAPK3—melanoma	5.89e-06	1.84e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CTNNB1—melanoma	5.89e-06	1.84e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MMP9—melanoma	5.88e-06	1.83e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—HRAS—melanoma	5.87e-06	1.83e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PTEN—melanoma	5.87e-06	1.83e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—KRAS—melanoma	5.87e-06	1.83e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—HRAS—melanoma	5.87e-06	1.83e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—CDKN1A—melanoma	5.86e-06	1.83e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PTEN—melanoma	5.85e-06	1.82e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—HRAS—melanoma	5.83e-06	1.82e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CXCL8—melanoma	5.82e-06	1.81e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—VEGFA—melanoma	5.82e-06	1.81e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—NFKB1—melanoma	5.82e-06	1.81e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—PIK3CA—melanoma	5.79e-06	1.81e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MMP9—melanoma	5.79e-06	1.8e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—HRAS—melanoma	5.78e-06	1.8e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MMP9—melanoma	5.77e-06	1.8e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—CDKN1A—melanoma	5.77e-06	1.8e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—STAT3—melanoma	5.76e-06	1.8e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—CDKN1A—melanoma	5.75e-06	1.79e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PTEN—melanoma	5.75e-06	1.79e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—NRAS—melanoma	5.75e-06	1.79e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PTEN—melanoma	5.74e-06	1.79e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MYC—melanoma	5.73e-06	1.79e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—NFKB1—melanoma	5.73e-06	1.78e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—NFKB1—melanoma	5.71e-06	1.78e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling by GPCR—AKT1—melanoma	5.7e-06	1.78e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—IL6—melanoma	5.7e-06	1.78e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MAPK3—melanoma	5.69e-06	1.77e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CDKN1B—melanoma	5.68e-06	1.77e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MAPK3—melanoma	5.66e-06	1.76e-05	CbGpPWpGaD
Mianserin—ADRA2A—GPCR downstream signaling—AKT1—melanoma	5.62e-06	1.75e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—IL6—melanoma	5.62e-06	1.75e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—IL6—melanoma	5.61e-06	1.75e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling by GPCR—AKT1—melanoma	5.61e-06	1.75e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—MAPK1—melanoma	5.61e-06	1.75e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—EGFR—melanoma	5.61e-06	1.75e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—TP53—melanoma	5.6e-06	1.75e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling by GPCR—AKT1—melanoma	5.6e-06	1.75e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ABCB1—melanoma	5.59e-06	1.74e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—IL6—melanoma	5.58e-06	1.74e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CASP3—melanoma	5.57e-06	1.74e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL2—melanoma	5.56e-06	1.73e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—IL6—melanoma	5.54e-06	1.72e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MYC—melanoma	5.53e-06	1.72e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK3—melanoma	5.51e-06	1.72e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MYC—melanoma	5.51e-06	1.72e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.47e-06	1.71e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—PIK3CA—melanoma	5.44e-06	1.69e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CCND1—melanoma	5.42e-06	1.69e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CD—melanoma	5.42e-06	1.69e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—MAPK1—melanoma	5.41e-06	1.69e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—EGFR—melanoma	5.41e-06	1.69e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—PIK3CA—melanoma	5.39e-06	1.68e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—MAPK1—melanoma	5.39e-06	1.68e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—EGFR—melanoma	5.39e-06	1.68e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CTNNB1—melanoma	5.37e-06	1.67e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—HRAS—melanoma	5.36e-06	1.67e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MYC—melanoma	5.36e-06	1.67e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—ALB—melanoma	5.35e-06	1.67e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—KRAS—melanoma	5.3e-06	1.65e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—VEGFA—melanoma	5.28e-06	1.65e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MMP9—melanoma	5.26e-06	1.64e-05	CbGpPWpGaD
Mianserin—OPRK1—Signaling Pathways—AKT1—melanoma	5.26e-06	1.64e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—CDKN1A—melanoma	5.25e-06	1.63e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—MAPK1—melanoma	5.24e-06	1.63e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—EGFR—melanoma	5.24e-06	1.63e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PTEN—melanoma	5.23e-06	1.63e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—STAT3—melanoma	5.23e-06	1.63e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CG—melanoma	5.22e-06	1.63e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—NRAS—melanoma	5.22e-06	1.63e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—TP53—melanoma	5.21e-06	1.62e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—NFKB1—melanoma	5.21e-06	1.62e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—VEGFA—melanoma	5.2e-06	1.62e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—VEGFA—melanoma	5.19e-06	1.62e-05	CbGpPWpGaD
Mianserin—HTR6—Signaling Pathways—AKT1—melanoma	5.18e-06	1.62e-05	CbGpPWpGaD
Mianserin—HTR7—Signaling Pathways—AKT1—melanoma	5.18e-06	1.61e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—STAT3—melanoma	5.15e-06	1.6e-05	CbGpPWpGaD
Mianserin—HTR1D—Signaling Pathways—AKT1—melanoma	5.15e-06	1.6e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PRKCA—melanoma	5.14e-06	1.6e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—STAT3—melanoma	5.13e-06	1.6e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—NRAS—melanoma	5.13e-06	1.6e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—IL6—melanoma	5.13e-06	1.6e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—NRAS—melanoma	5.12e-06	1.6e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—KRAS—melanoma	5.11e-06	1.59e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling by GPCR—AKT1—melanoma	5.11e-06	1.59e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ERCC2—melanoma	5.1e-06	1.59e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—KRAS—melanoma	5.09e-06	1.59e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PPARG—melanoma	5.04e-06	1.57e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK3—melanoma	5e-06	1.56e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—HRAS—melanoma	4.99e-06	1.55e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—KRAS—melanoma	4.95e-06	1.54e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK3—melanoma	4.92e-06	1.53e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK3—melanoma	4.91e-06	1.53e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—PIK3CA—melanoma	4.87e-06	1.52e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MYC—melanoma	4.86e-06	1.51e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MYC—melanoma	4.78e-06	1.49e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—IL6—melanoma	4.77e-06	1.49e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MYC—melanoma	4.77e-06	1.49e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—MAPK1—melanoma	4.75e-06	1.48e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—EGFR—melanoma	4.75e-06	1.48e-05	CbGpPWpGaD
Mianserin—HTR2B—Signaling Pathways—AKT1—melanoma	4.73e-06	1.47e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—VEGFA—melanoma	4.73e-06	1.47e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CB—melanoma	4.72e-06	1.47e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—TP53—melanoma	4.71e-06	1.47e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—PIK3CA—melanoma	4.7e-06	1.46e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—STAT3—melanoma	4.68e-06	1.46e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—MAPK1—melanoma	4.68e-06	1.46e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTGS2—melanoma	4.68e-06	1.46e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—EGFR—melanoma	4.68e-06	1.46e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—PIK3CA—melanoma	4.67e-06	1.46e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—NRAS—melanoma	4.67e-06	1.46e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—MAPK1—melanoma	4.67e-06	1.45e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—EGFR—melanoma	4.67e-06	1.45e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CD—melanoma	4.59e-06	1.43e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—PIK3CA—melanoma	4.55e-06	1.42e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—TP53—melanoma	4.54e-06	1.42e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—ALB—melanoma	4.53e-06	1.41e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—TP53—melanoma	4.52e-06	1.41e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—HRAS—melanoma	4.5e-06	1.4e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—KRAS—melanoma	4.49e-06	1.4e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK3—melanoma	4.47e-06	1.39e-05	CbGpPWpGaD
Mianserin—ADRA2C—Metabolism—AKT1—melanoma	4.44e-06	1.38e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—KRAS—melanoma	4.42e-06	1.38e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—PIK3CA—melanoma	4.42e-06	1.38e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—KRAS—melanoma	4.41e-06	1.37e-05	CbGpPWpGaD
Mianserin—DRD3—Signaling Pathways—AKT1—melanoma	4.4e-06	1.37e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—TP53—melanoma	4.4e-06	1.37e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MYC—melanoma	4.35e-06	1.36e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—HRAS—melanoma	4.35e-06	1.35e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—HRAS—melanoma	4.32e-06	1.35e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—IL6—melanoma	4.31e-06	1.34e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—MAPK1—melanoma	4.26e-06	1.33e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—EGFR—melanoma	4.25e-06	1.33e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—HRAS—melanoma	4.21e-06	1.31e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—IL6—melanoma	4.16e-06	1.3e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—PIK3CA—melanoma	4.14e-06	1.29e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—IL6—melanoma	4.14e-06	1.29e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—PIK3CA—melanoma	4.12e-06	1.29e-05	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PTEN—melanoma	4.08e-06	1.27e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—PIK3CA—melanoma	4.06e-06	1.26e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—PIK3CA—melanoma	4.05e-06	1.26e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CG—melanoma	4.03e-06	1.25e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—IL6—melanoma	4.03e-06	1.25e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—KRAS—melanoma	4.02e-06	1.25e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CB—melanoma	4e-06	1.25e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—TP53—melanoma	3.99e-06	1.24e-05	CbGpPWpGaD
Mianserin—ADRA2B—Signaling Pathways—AKT1—melanoma	3.98e-06	1.24e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTGS2—melanoma	3.96e-06	1.23e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—TP53—melanoma	3.93e-06	1.22e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—TP53—melanoma	3.92e-06	1.22e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PPARG—melanoma	3.89e-06	1.21e-05	CbGpPWpGaD
Mianserin—HTR1A—Signaling Pathways—AKT1—melanoma	3.84e-06	1.2e-05	CbGpPWpGaD
Mianserin—HTR2C—Signaling Pathways—AKT1—melanoma	3.82e-06	1.19e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—HRAS—melanoma	3.82e-06	1.19e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—HRAS—melanoma	3.76e-06	1.17e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—HRAS—melanoma	3.75e-06	1.17e-05	CbGpPWpGaD
Mianserin—ADRA2C—Signaling Pathways—AKT1—melanoma	3.71e-06	1.16e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—PIK3CA—melanoma	3.69e-06	1.15e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—IL6—melanoma	3.65e-06	1.14e-05	CbGpPWpGaD
Mianserin—ADRA2A—Metabolism—AKT1—melanoma	3.61e-06	1.12e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—IL6—melanoma	3.59e-06	1.12e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—IL6—melanoma	3.59e-06	1.12e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—TP53—melanoma	3.57e-06	1.11e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CD—melanoma	3.54e-06	1.1e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—ALB—melanoma	3.5e-06	1.09e-05	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PTEN—melanoma	3.46e-06	1.08e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—HRAS—melanoma	3.42e-06	1.06e-05	CbGpPWpGaD
Mianserin—CYP2B6—Metabolism—AKT1—melanoma	3.38e-06	1.05e-05	CbGpPWpGaD
Mianserin—DRD2—Signaling Pathways—AKT1—melanoma	3.37e-06	1.05e-05	CbGpPWpGaD
Mianserin—HTR2A—Signaling Pathways—AKT1—melanoma	3.32e-06	1.03e-05	CbGpPWpGaD
Mianserin—HRH1—Signaling Pathways—AKT1—melanoma	3.31e-06	1.03e-05	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—IL6—melanoma	3.27e-06	1.02e-05	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CB—melanoma	3.09e-06	9.62e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTGS2—melanoma	3.06e-06	9.53e-06	CbGpPWpGaD
Mianserin—ADRA2A—Signaling Pathways—AKT1—melanoma	3.02e-06	9.4e-06	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—PIK3CA—melanoma	2.88e-06	8.97e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PTEN—melanoma	2.67e-06	8.31e-06	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—PIK3CA—melanoma	2.44e-06	7.6e-06	CbGpPWpGaD
Mianserin—CYP2D6—Metabolism—AKT1—melanoma	2.35e-06	7.32e-06	CbGpPWpGaD
Mianserin—CYP1A2—Metabolism—AKT1—melanoma	1.99e-06	6.2e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—PIK3CA—melanoma	1.88e-06	5.86e-06	CbGpPWpGaD
Mianserin—CYP3A4—Metabolism—AKT1—melanoma	1.54e-06	4.79e-06	CbGpPWpGaD
